NewsBenzingaReported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval Benzinga 2026.11.05 07:13 (GMT+0) Open on Benzinga Other news Avalo Therapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed Wells Fargo CIB CEO Fernando Rivas Says Our Corporate Investment Banking Pipelines Are At An All-Time High Lipocine Q3 EPS $(0.08) Beats $(0.32) Estimate, Sales $2.290M Beat $159.500K Estimate McDonald's To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Thursday Susquehanna Maintains Positive on GATX, Raises Price Target to $220 SCYNEXIS Q3 EPS $(0.71) Beats $(0.72) Estimate
Wells Fargo CIB CEO Fernando Rivas Says Our Corporate Investment Banking Pipelines Are At An All-Time High
